Liudmila Lipatova

Ms. Liudmila Lipatova

orcid

Research Focus & Metrics

Academic Career Length

2Years (2025-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
Verified
Journal Article
Open access
PDF file
MPMichail Peklo
Michail Peklo
ESE. V. Smolyakova
E. V. Smolyakova
LLLiudmila Lipatova
Liudmila Lipatova
NKNatal’ya M. Kashirina
Natal’ya M. Kashirina
YSYurij S. Skoblov
Yurij S. Skoblov
TVTat’yana N. Vlasik
Tat’yana N. Vlasik
β-adrenoreceptor (ADRB) ligands are actively used in the therapy of bronchopulmonary and cardiovascular diseases. When using these drugs, it is important to assess changes in ADRB content in different tissues. In most cases, the direct measurement of ADRB content in lung and heart cells is not possible. ADRB2 content in peripheral blood lymphocytes (or mononuclear cells) was shown to correlate with that in myocardial cells. It has been suggested that blood lymphocytes can be used to monitor ADRB content in solid organs. However, the estimation of ADRB1 content in myocardium from its content in peripheral lymphocytes is not possible due to the low content of ADRB1 in lymphocytes. In the present study, we performed simultaneous determination of ADRB1 and ADRB2 both in the total population of PBMCs and in isolated subpopulations of monocytes, T-lymphocytes, and NK-cells from 23 healthy donors using the modified radioligand method. The highest amount of ADRB2 was detected in NK cells, followed by PBMCs, monocytes, and T cells. The content of these receptors in all blood cell subpopulations was significantly correlated with each other, suggesting the possibility of using PBMCs to monitor ADRB2 in solid organs. For the first time, ADRB1 was detected in monocytes and NK cells.

4 June 2025 in Life
Verified
Journal Article
Open access
PDF file
Popov MikhailPopov Mikhail
Popov Mikhail
SDSiarhei Dabravolski
Siarhei Dabravolski
VDVladislav Dontsov
Vladislav Dontsov
СВСергей Взваров
Сергей Взваров
ЕАЕвгений Агафонов
Евгений Агафонов
DSDmitry Shumakov
Dmitry Shumakov
Background: Matrix metalloproteinase 9 (MMP9) has recently emerged as a risk predictor in patients with cardiovascular diseases (CVD). However, little is known regarding the significance of elevated plasma MMP9 levels in patients during the long-term period following myocardial revascularisation. We aimed to investigate the role of MMP9 in relation to myocardial status before and after myocardial revascularisation and to assess its long-term prognostic value. Methods: This prospective observational study included 200 male patients with ischaemic heart disease. All patients underwent direct myocardial revascularisation on a beating heart (off-pump surgery). Plasma MMP9 levels were analysed preoperatively, at 48 h postoperatively, and during the long-term follow-up period (one year postoperatively). Key echocardiographic parameters, specifically left ventricular ejection fraction (LVEF) and Left Ventricular End-Diastolic Volume (LVEDV), were also assessed. Results: MMP9 levels decreased significantly at 48 h postoperatively (p < 0.0001). During the long-term postoperative period, a clear relationship was demonstrated: higher 1-year MMP9 levels were associated with lower 1-year LVEF, whilst lower 1-year MMP9 levels were associated with higher 1-year LVEF. No significant correlation was observed between preoperative MMP9 levels and age or most other baseline laboratory parameters. Conclusions: Our study established an association between 1-year postoperative MMP9 levels and key parameters of left ventricular function during the long-term follow-up period. This suggests that MMP9 may serve as a novel biomarker for predicting outcomes following myocardial revascularisation.

1 January 2026 in Cardiology: News, Opinions, Training
Verified
Journal Article
Closed access
MPMichail Peklo
Michail Peklo
LLLiudmila Lipatova
Liudmila Lipatova
TST.S. Sukhinina
T.S. Sukhinina
NKN.M. Kashirina
N.M. Kashirina
EYE.V. Yanushevskaya
E.V. Yanushevskaya
TVT.N. Vlasik
T.N. Vlasik